1. Introduction {#sec1}
===============

Type 2 diabetes (T2D) is one of the leading causes of mortality worldwide, largely due to vascular complications including myocardial infarction and stroke \[[@B1], [@B2]\]. Endothelial function, a key determinant of vascular health, is impaired in the diabetic vasculature primarily due to reduced nitric oxide (NO) bioavailability that is brought about by a combination of uncoupling and inhibition of endothelial nitric oxide synthase (eNOS) and an excessive production of reactive oxygen species (ROS) \[[@B3]\]. Loss of NO bioactivity, leading to endothelial dysfunction, is known to predispose patients to developing secondary complications such as stroke \[[@B4]\]. Therefore understanding the mechanisms associated with vascular dysfunction is critical to the development of therapeutic targets in the hope of preventing T2D-related morbidity.

The NAD^+^-dependent deacetylase, sirtuin 1 (SIRT1), is abundantly expressed in the vasculature \[[@B5]\] and deacetylates a number of substrates that are key modulators of vascular function including eNOS \[[@B6]\] and FOXO1 \[[@B7]\]. SIRT1 has been reported to be downregulated in peripheral blood mononuclear cells of obese humans \[[@B8]\] and in the liver and pancreas of rodents on a high-fat diet \[[@B9]\]. The effect of T2D on microvascular SIRT1 expression is less clear. High-fat feeding resulted in a significant decrease in mouse aorta SIRT1 protein expression \[[@B10]\], while no changes were seen in the cerebral vasculature in obese Zucker rats \[[@B11]\].

SIRT1 interacts with specific double-stranded repeat sequences of DNA at the extremities of chromosomes \[5′-(TTAGGG)~n~-3′\], known as telomeres \[[@B12]\]. During each round of cell division, telomeres shorten until they reach a critical length \[[@B13]\]. At this point, the cell can no longer replicate and it becomes either senescent or apoptotic, thereby creating an accelerated aging phenotype and increasing risk of secondary disease \[[@B14]\]. Telomere shortening can be prematurely accelerated*in vitro* in the face of oxidative stress \[[@B15]\], a hallmark of T2D \[[@B16]\]. Therefore restoring telomere health may be an important therapeutic target in preventing vascular complications of T2D. Although epidemiological studies have suggested an association between T2D and shortened leukocyte telomeres \[[@B17], [@B18]\], a direct cause and effect relationship has never been established. Moreover it is not known whether vascular telomeres have accelerated shortening in T2D.

2. Materials and Methods {#sec2}
========================

2.1. Animal Model of Type 2 Diabetes {#sec2.1}
------------------------------------

All animal procedures were carried out in accordance with the Australian Code for the Responsible Conduct of Research and were approved by the Flinders University Animal Ethics Committee. Male hooded Wistar rats (*n* = 17) were bred and housed under controlled room temperature with a 12 : 12 hour light-dark cycle in the School of Medicine Animal Care Facility at Flinders University.

After weaning at three weeks of age, rats were randomly assigned into two groups: diabetic and control. The diabetic group (*n* = 9; T2D) was placed on a high-fat diet which consisted of 45 kcal% fat, 35 kcal% carbohydrate, and 20 kcal% protein (D12451; Open Source Diet). The chow was custom-made by Gordon\'s specialty stockfeed (Yanderra, Australia). The remaining group (*n* = 8; control) was maintained on a control diet which contained 10 kcal% fat, 70 kcal% carbohydrate, and 20 kcal% protein (D12450H; Open Source Diet). Animals had free access to water and their assigned diets. After 18 weeks on the diet regimen, the diabetic group was given an intraperitoneal injection of streptozotocin (30 mg/kg body weight) dissolved in saline while the control group was injected with the same volume of vehicle. Both groups were maintained on their respective diets for an additional eight weeks. A timeline is shown in [Figure 1](#fig1){ref-type="fig"}. Previous studies have shown that a high-fat feeding followed by a low dose of streptozotocin induces a mild impairment of insulin secretion, similar to that seen in late stage T2D \[[@B19]\].

2.2. Measurement of Blood Pressure {#sec2.2}
----------------------------------

Five days prior to sacrifice, rats were anesthetized with 3% isoflurane and their body temperature was maintained on a heating pad at 37°C. Blood pressure was measured using MLT125/R pulse transducer/pressure cuff and IN125 NIBP controller (AD Instruments, Australia) and recorded using PowerLab software (AD Instruments, Australia). Systolic pressure was determined from the average of three consecutive readings obtained from each rat.

2.3. Sample Collection {#sec2.3}
----------------------

On the day of sacrifice, animals were weighed and anesthetized with isoflurane. Blood glucose was measured from the tail vein using an Accu-Chek Performa glucometer and test strips (Roche Diagnostics, Indianapolis, IN, USA). The animals were then decapitated using a rodent guillotine and trunk blood obtained for measurement of serum insulin and free fatty acids, plasma triglycerides, and C-reactive protein (CRP) and for extraction of DNA using a DNeasy blood and tissue kit (Qiagen) according to the manufacturer\'s instructions. The DNA concentration of each extraction was measured in triplicate using a NanoDrop 2000 (Thermo Scientific).

The left and right femoral artery were excised from animals, cleaned of connective tissue, and washed to remove blood. The size of each artery was 0.9 cm in length, 2 mm in en face width, and approximately 1 mg in weight. Arteries were immediately snap frozen in liquid nitrogen and stored at −80°C. DNA was extracted using a QIAamp DNA micro kit (Qiagen) according to the manufacturer\'s instructions and stored at −80°C until analysis.

The brain was removed and the middle cerebral arteries were carefully harvested and pooled into 180 *µ*L modified radioimmunoprecipitation (RIPA) buffer containing 50 mM Tris, pH 7.8 with 150 mM NaCl, 1% Triton X-100, 0.5% Nonidet P-40, 0.25% sodium deoxycholate, and 1 mM PMSF and protease inhibitor cocktail (Roche, Indianapolis, IN, USA). Total protein was extracted as previously described \[[@B20]\] and stored at −80°C.

2.4. Immunoblotting {#sec2.4}
-------------------

Total protein was measured using EZQ Protein Quantitation (Roche Diagnostics, Indianapolis, IN, USA). Cerebral artery lysate was then combined with Laemmli sample buffer and heated to 95°C for 5 mins. Equal amounts of protein (18 micrograms) were loaded onto each lane of a stain-free gel (Bio-Rad Laboratories, Hercules, CA, USA) alongside Dual Color Precision Plus protein standard (Bio-Rad Laboratories). Total protein loaded on the gel and then transferred to the low fluorescence polyvinylidene difluoride (PVDF) membrane was imaged (ChemiDoc MP imager, Bio-Rad Laboratories) and analysed using Image Lab 4.0.1 software (Bio-Rad Laboratories). Previous studies have shown that this method of protein normalization is superior to that of either total protein stains (e.g., Sypro Ruby, Amido Black, and Coomassie Blue) or antibody loading controls \[[@B21]\].

Membranes were probed with an antibody directed against either SIRT1 (Abcam), eNOS (BD Transduction Labs), Nox2 (BD Transduction Laboratories), manganese superoxide dismutase (MnSOD; Millipore), p66^Shc^ (Millipore), or 3-nitrotyrosine (Abcam) overnight at 4°C. The next day, membranes were washed and incubated with the appropriate secondary antibody (Jackson ImmunoResearch). Bands were visualized using enhanced chemiluminescence, captured with a digital acquisition system (Fujifilm, Japan) and quantified (Carestream Molecular Imaging software, Rochester, NT, USA). Densitometry results are expressed relative to total protein and normalized to the control group.

2.5. Singleplex Telomere qPCR Assay {#sec2.5}
-----------------------------------

Mean telomere length was measured using a singleplex assay similar to that described by Cawthon \[[@B22]\]. The telomere and single-copy gene (*β*-actin) were amplified in separate singleplex reactions because the efficiency of each amplicon was optimal in different mastermixes (assessed in pilot studies). The telomere primers were used as previously described by Cawthon \[[@B23]\] and used at a concentration of 900 nM. The single-copy gene (*β*-actin) primer sequences (written 5′ → 3′) were *β*-actin-F, AGG TCA TCA CTA TCG GCA ATG A, and *β*-actin-R, GAG ACT ACA ACT TAC CCA GGA AGG AA, and used at a final concentration of 2 *µ*M.

Each qPCR reaction was conducted in a total volume of 20 *µ*L using 384-well plates and performed on a ViiA 7 real-time PCR instrument (Life Technologies, Foster City, CA). The telomere assay was amplified in a custom-made mastermix as described by Cawthon \[[@B23]\] and the *β*-actin assay was amplified in Power SYBR green PCR mastermix (Life Technologies).

For the telomere assay, a standard curve was run alongside the experimental samples consisting of a calibrator DNA sample which was diluted serially by 5-fold to produce five concentrations of DNA ranging from 515 to 0.824 ng/mL. For the *β*-actin assay, a standard curve was run alongside the experimental samples consisting of the same calibrator DNA sample which was diluted serially by 5-fold to produce five concentrations of DNA ranging from 5150 to 8.24 ng/mL. The calibrator was rat DNA extracted from either whole blood or femoral artery.

2.6. Telomere Data Analysis {#sec2.6}
---------------------------

The amount of telomere was calculated as *T* = *E* ^(Cq~calibrator~\ −\ Cq~sample~)^, where *E* was the efficiency of the telomere primer calculated from the standard curve, Cq~calibrator~ was the Cq of the 1 : 5 dilution on the standard curve, and Cq~sample~ was the Cq of the experimental sample. The amount of *β*-actin (reference gene) was calculated as *S* = *E* ^(Cq~calibrator~\ −\ Cq~sample~)^, where *E* was the efficiency of the *β*-actin primer calculated from the standard curve, Cq~calibrator~ was the Cq of the 1 : 5 dilution on the standard curve, and Cq~sample~ was the Cq of the experimental sample. Relative telomere length (*T*/*S*) was estimated as the ratio between the amount of telomere (*T*) and reference gene (*S*).

2.7. Drugs and Reagents {#sec2.7}
-----------------------

Streptozotocin was purchased from Sigma. Fresh streptozotocin stock solutions of 50 mg/mL were made in saline. The *β*-actin and telomere primers were synthesized by GeneWorks (Thebarton, SA, Australia) and dissolved in water for injection (GlaxoSmithKline).

2.8. Statistical Analysis and Power {#sec2.8}
-----------------------------------

All data are expressed as mean ± standard error of the mean. Statistical comparisons were performed using GraphPad InStat version 3 software (GraphPad software, La Jolla, CA, USA) using an unpaired *t*-test. Statistical significance was accepted at *P* \< 0.05. The initial power analysis was performed based on previous telomere length studies in rodents \[[@B24], [@B25]\]. The experiment was powered at 80% to detect a 20% change in telomere length, assuming a two-tailed alpha level of 5%.

3. Results {#sec3}
==========

3.1. Phenotypic Assessment of Animals Fed a High-Fat Diet followed by a Low Dose of Streptozotocin {#sec3.1}
--------------------------------------------------------------------------------------------------

Rats fed a high-fat diet for 18 weeks weighed significantly more than age-matched control rats fed a control diet (*P* = 0.029; see [Table 1](#tab1){ref-type="table"}). Animals then received either a low dose of streptozotocin or vehicle and the diet regimen was continued for another eight weeks. One rat died just prior to streptozotocin injection and two rats died the following week after streptozotocin injection. Systolic blood pressure was similar in both T2D rats and control rats (*P* = 0.16; 113 ± 8 mmHg versus 105 ± 5 mmHg, resp.). On the day of sacrifice, T2D rats weighed significantly less than the control group (*P* = 0.0001; 358 ± 12 g versus 432 ± 7 g, resp.).

Fasting plasma glucose levels were significantly higher in T2D rats compared to control rats (*P* \< 0.0001; 24.2 ± 1.3 mM versus 8.6 ± 0.3 mM, resp.). Circulating free fatty acid concentration was significantly elevated in T2D rats compared to control rats (*P* = 0.012; 0.51 ± 0.06 mM versus 0.34 ± 0.02 mM, resp.). Plasma insulin concentration was significantly lower in T2D rats compared to the control rats (*P* = 0.0028; 0.5 ± 0.1 ng/mL versus 2.8 ± 0.5 ng/mL, resp.), a reflection of streptozotocin-induced pancreatic *β*-cell dysfunction. As a marker of systemic inflammation, plasma CRP was significantly elevated in T2D compared to control rats (*P* \< 0.0001; see [Table 1](#tab1){ref-type="table"}).

3.2. Mean Telomere Length in Femoral Artery and Whole Blood {#sec3.2}
-----------------------------------------------------------

As shown in [Figure 2(a)](#fig2){ref-type="fig"}, arterial telomere length was comparable between T2D rats and control rats (*P* = 0.28; 0.92 ± 0.04 versus 0.81 ± 0.08, resp.). However leukocyte telomere length was significantly shorter in T2D compared to the control group (*P* = 0.034; 0.49 ± 0.14 versus 1.09 ± 0.19, resp.). The percent efficiency of *β*-actin and telomere primers ranged between 92 and 102%. The PCR amplification products were visualized by agarose gel electrophoresis, ethidium bromide staining, and UV transillumination (see [Figure 2(b)](#fig2){ref-type="fig"}). The *β*-actin PCR product was observed at the expected size of 81 base pairs while the telomere PCR product showed a main product at 82 base pairs (the sum of the length of the two telomere primers) and a smear to 150 base pairs, reflecting longer PCR products due to staggered annealing of the primers. This is consistent with other reports in the literature \[[@B22], [@B26]\].

3.3. Vascular Protein Expression {#sec3.3}
--------------------------------

Vascular SIRT1 and eNOS protein expression were significantly lower in T2D rats compared to their control counterparts (*P* = 0.0082 and *P* = 0.011, resp.; see [Figure 3](#fig3){ref-type="fig"}). MnSOD and p66Shc protein levels were significantly lower in T2D rats compared to control rats (*P* = 0.039 and *P* = 0.028, resp.); however total 3-nitrotyrosine-containing proteins and Nox2 were comparable between groups ([Figure 4](#fig4){ref-type="fig"}).

4. Discussion {#sec4}
=============

There are two major findings of the present study. Firstly, we have demonstrated that T2D causes selective accelerated telomere shortening in circulating leukocytes but preserved telomere length in arteries. To our knowledge, this is the first direct evidence of leukocyte telomere shortening in T2D. Secondly, although hyperglycemia leads to blunted SIRT1 \[[@B27]\] and telomere shortening \[[@B28]\], we have shown*in vivo* that hyperglycemia and a deficit in vascular SIRT1*per se* are not sufficient to prematurely shorten vascular telomeres.

4.1. Phenotype of T2D Rats {#sec4.1}
--------------------------

Here we have shown that rats gained significantly more weight after an 18-week high-fat diet regimen (see [Table 1](#tab1){ref-type="table"}). Injection of a low dose of streptozotocin significantly increased blood glucose levels in T2D rats, which is consistent with other reports \[[@B29]\]. Circulating insulin levels were significantly decreased, a feature of clinical late stage T2D when the pancreatic beta cells become impaired and insulin secretion is reduced \[[@B30]\]. The animals also showed evidence of dyslipidemia that is in line with elevated plasma free fatty acids observed in human T2D \[[@B31]\] that has been linked to the onset of insulin resistance \[[@B32]\]. The T2D rats in our study had significantly elevated levels of CRP, confirming that this animal model is a good representation of T2D in humans which is associated with prolonged low-grade inflammation \[[@B33]\].

4.2. Leukocyte Telomere Length Is Shorter in T2D {#sec4.2}
------------------------------------------------

We found that leukocyte telomere length is shorter in T2D rats compared to control rats. Our findings are in line with accumulating clinical studies showing a correlation between T2D and shorter leukocyte telomeres \[[@B17], [@B18], [@B34], [@B35]\]. One possible explanation for the shorter leukocyte telomeres in T2D is that it reflects increased leukocyte turnover due to the systemic low-grade inflammation. However clinical studies have failed to show a significant inverse correlation between leukocyte telomere length and markers of inflammation \[[@B35]--[@B37]\]. Tentolouris and colleagues \[[@B38]\] have previously reported a correlation between telomere length and nitrosative stress. Taken together, we speculate that the observed leukocyte telomere attrition may be due, at least in part, to nitrosative stress which is absent within the vasculature in this animal model of T2D (see below).

4.3. Vascular Telomere Length Is Comparable in T2D and Controls {#sec4.3}
---------------------------------------------------------------

Shortened vascular telomere length has been previously documented in human coronary heart disease \[[@B39]\], atherosclerosis \[[@B40]\], and abdominal aortic aneurysms \[[@B41]\]. Because vascular biopsies cannot be taken from obese or T2D patients without overt vascular pathology, leukocyte telomere measurements have been used as a surrogate for predicting vascular disease risk \[[@B42]\]. We have shown for the first time that arterial telomere length is preserved in T2D rats compared to control rats. Although SIRT1 depletion \[[@B43]\] and hyperglycemia \[[@B28]\] have previously been shown to independently accelerate telomere shortening, our results have shown that hyperglycemia and blunted vascular SIRT1*in vivo* were not sufficient to prematurely shorten arterial telomeres. Our experiments were sufficiently powered at 80% to detect a 20% change in telomere length. Therefore a smaller change in telomere length would not have been detected and as a result we cannot rule out the possibility that there are more subtle changes in telomere length within the T2D vasculature. Nevertheless our data suggests that leukocyte telomere length may not be an optimal surrogate for vascular telomere length in T2D.

4.4. Vascular SIRT1 and eNOS Protein Expression Are Reduced in T2D {#sec4.4}
------------------------------------------------------------------

SIRT1 protein expression was significantly decreased in resistance-sized vessels harvested from T2D rats compared to control rats on a normal diet (standard chow). Our findings are in line with studies showing a decline in SIRT1 levels at the level of the macrovasculature (aorta) after six months of high-fat feeding \[[@B10]\]. However it is important to assess protein expression within the resistance-sized vessels, since these vessels are fundamental to the control of blood flow \[[@B44]\]. We have now confirmed for the first time that SIRT1 protein expression is blunted within the microvasculature in T2D.

The mechanisms leading to a decline in SIRT1 expression in T2D are incompletely understood. SIRT1 activity has been shown to be controlled by both nutritional status and the cellular redox status (NAD^+^/NADH ratio). In a nutrient rich environment, NAD^+^/NADH ratio is blunted due to an increased rate of reduction of NAD^+^ to NADH, leading to a decrease in SIRT1 activity \[[@B10]\]. Endothelial progenitor cells \[[@B45]\], human umbilical vein endothelial cells \[[@B27]\], and mouse brain endothelial cells (Sokoya et al., unpublished findings) cultured in high glucose have lower levels of SIRT1 protein expression. Recent studies have also shown that oxidative stress directly inhibits SIRT1 activity via oxidative posttranslational modifications \[[@B46]\]. Therefore, both a reduction in cellular redox status and an increase in oxidant stress may be working together to reduce vascular SIRT1 expression.

NO is an important signalling molecule in the vascular system. The production of endothelial-derived NO is key in mediating relaxation of the cerebral vasculature \[[@B47]\]. Our study has found that T2D leads to significantly lower eNOS protein levels within cerebral arteries. This may be mediated in part by CRP, which has been shown to directly decrease eNOS protein expression and activity \[[@B48]\] and/or hyperglycemia that promotes eNOS glycosylation thereby reducing the active form of NO \[[@B49]\]. A reduction in total eNOS production suggests that NO bioavailability may be reduced, potentially leading to blunted endothelial-mediated relaxations, which have previously been shown in this model \[[@B50]\].

4.5. Vascular Antioxidant Protein Expression Is Reduced in T2D {#sec4.5}
--------------------------------------------------------------

Our observation that vascular MnSOD protein expression is blunted in T2D suggests that the antioxidant pathway is being overwhelmed, presumably due to an increase in superoxide production within the vasculature. This is consistent with other data showing downregulation of MnSOD in the vasculature after high-fat feeding \[[@B51]\].

Vascular p66Shc protein expression was also significantly lower in T2D rats compared to controls. As a redox mitochondrial enzyme, p66Shc has been shown to generate mitochondrial ROS (hydrogen peroxide) \[[@B52]\]. However more recent studies have localized p66Shc to the cytoplasm where it is regulated by the redox sensitive transcription factor, NFE2-related factor 2 (Nrf2) \[[@B53]\]. Nrf2 regulates the antioxidant response element (ARE/EpRE) mediated expression of antioxidant enzymes. In this way, cytosolic p66Shc serves as an antioxidant protein. Our finding of blunted vascular p66Shc protein levels in T2D is in accordance with a recent report of reduced Nrf2 signaling in mouse brain after high-fat feeding \[[@B54]\].

Interestingly, SIRT1 itself has been shown to play an important role in regulating antioxidant gene expression in endothelial cells by enhancing the stability of the FoxO3a/PGC-1*α* complex, which promotes antioxidant gene expression \[[@B7]\]. In this way, blunted vascular SIRT1 in T2D could mediate, at least in part, the observed decrease in antioxidant protein expression.

4.6. Source of Vascular Superoxide {#sec4.6}
----------------------------------

Vascular NADPH oxidases are one of the major sources of ROS in the cardiovascular system \[[@B55]\]. In our study, we examined a subunit of NADPH oxidase, Nox2, which has previously shown to be significantly increased in mouse aorta after high-fat feeding \[[@B56]\]. However, in our animal model of T2D, Nox2 levels were uncompromised in cerebral artery homogenates. Nevertheless there are additional sources of superoxide including cyclooxygenase \[[@B57]\], xanthine oxidase \[[@B58]\], and other NADPH oxidases such as Nox1 and Nox5 \[[@B55]\].

4.7. Nitrosative Stress {#sec4.7}
-----------------------

Superoxide can react with NO to form peroxynitrite which in turn promotes nitration of tyrosine residues in proteins leading to nitrotyrosine-containing proteins. In the present study, we found that the abundance of nitrotyrosine-modified proteins was comparable in cerebral artery lysate from T2D rats compared to control rats. This is in contrast to studies in mouse aorta \[[@B59]\], rat aorta \[[@B60]\], pig coronary artery \[[@B61]\], and rat epineurial arterioles \[[@B62]\] that have shown increased nitrotyrosine expression following high-fat feeding. Taken together, our data suggest that, although antioxidant defence capacity is reduced, there appears to be no vascular nitrosative stress in our experimental model of T2D.

4.8. Concluding Remarks {#sec4.8}
-----------------------

A number of caveats need to be recognised here in terms of interpretation of our data. Firstly, markers of oxidative and nitrosative stress were measured within the cerebral vasculature while telomere length was measured in DNA extracted from the peripheral vasculature. Ideally, telomere length would have been measured within cerebral arteries; however this was impossible given the small size of rodent cerebral arteries. Secondly, the femoral artery comprises a single layer of endothelial cells and a few layers of smooth muscle cells. Therefore the smooth muscle component largely outweighs the endothelial component. If there are changes in endothelial cell telomere length in the absence of smooth muscle cell changes, these would not be detected. Thirdly, the qPCR assay as used in the present study measures mean telomere length. There is evidence that a cell may be triggered to enter senescence by a single critically short telomere \[[@B63]\]. Therefore it remains a possibility that there is telomere dysfunction within the T2D vasculature, driven by a small number of critically short telomeres. Future studies could address this possibility using high-throughput quantitative fluorescence*in situ* hybridization \[[@B64]\].

In summary, we have shown for the first time that leukocyte telomere length does not predict arterial telomere length in T2D rats. Our findings highlight the importance of measuring telomere dynamics in tissues other than circulating immune cells.
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![Timeline depicting the initiation of the assigned diet (high-fat or control diet), administration of streptozotocin or vehicle, blood pressure measurement, and tissue harvesting followed by termination.](JDR2015-153829.001){#fig1}

![(a) Leukocyte *T*/*S* ratio was significantly lower in T2D rats compared to control rats (*P* = 0.034; *t*-test). Femoral artery *T*/*S* ratio was comparable between T2D and control rats (*P* = 0.28). (b) qPCR products for rat *β*-actin and telomere primers. Lane 1: DNA ladder; lanes 2 and 6: rat leukocyte calibrator DNA; lanes 3 and 7: control rat leukocyte DNA; lanes 4 and 8: T2D rat leukocyte DNA; lanes 5 and 9: no template control (H~2~O).](JDR2015-153829.002){#fig2}

![Arterial protein expression levels of SIRT1 and eNOS were decreased in T2D rats compared to control rats (*n* = 3 each; *P* = 0.0082 and *P* = 0.011, resp.; *t*-test). Representative immunoblots are shown below the summary data. Relative protein levels were calculated as the ratio of the intensity of the chemiluminescent bands to the intensity of the total protein loaded on the gel and are expressed as a percentage of the values measured in control rats.](JDR2015-153829.003){#fig3}

![Arterial protein expression levels of MnSOD and p66Shc, but not Nox2 or 3-NT, were significantly decreased in T2D rats compared to control rats (*n* = 3 each; *P* = 0.039 and *P* = 0.028, resp.;*t*-test). Representative immunoblots are shown below the summary data. Relative protein levels were calculated as the ratio of the intensity of the chemiluminescent bands to the intensity of the total protein loaded on the gel and are expressed as a percentage of the values measured in control rats.](JDR2015-153829.004){#fig4}

###### 

Phenotype of control (*n* = 8) and T2D (*n* = 6) rats. Values are presented as mean ± standard error of the mean. *∗* indicates *P* \< 0.05 between T2D and control.

                             Control       T2D           *P* value
  -------------------------- ------------- ------------- ---------------
  Weight at injection (g)    387 ± 5       413 ± 9       0.029^*∗*^
  Final weight (g)           432 ± 7       358 ± 12      0.0001^*∗*^
  Systolic pressure (mmHg)   105 ± 5       113 ± 5       0.15
  Glucose (mM)               8.6 ± 0.3     24.2 ± 1.3    \<0.0001^*∗*^
  Insulin (ng/mL)            2.8 ± 0.5     0.5 ± 0.1     0.0028^*∗*^
  Triglycerides (mM)         1.4 ± 0.1     2.0 ± 0.4     0.14
  Free fatty acids (mM)      0.34 ± 0.02   0.51 ± 0.06   0.012^*∗*^
  CRP (ng/mL)                16 ± 0.7      263 ± 23      \<0.0001^*∗*^
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